- Company
- Propecia is sold in a new package
- by Apr 13, 2022 06:02am
- Organon Korea announced on the 11th that it will introduce a new package of the oral male hair loss treatment Propecia (Finasteride). As for the new package, it applied CI of Organon Korea company. Propecia, which has been sold by MSD Korea for more than 20 years since its launch in Korea in 2000, was officially launched and relocated by Orga
- Company
- KRPIA BOD meets Oh Chang-hyun, the new head
- by Eo, Yun-Ho Apr 12, 2022 06:05am
- KRPIA BOD will hold its first face-to-face meeting with Oh Chang-hyun, director of the MOHW's insurance pharmaceutical dept. According to related industries, KRPIA Board of Director (BOD) will hold a meeting with Oh Chang-hyun, the new manager, and members of the MOHW's Insurance and Pharmaceutical Affairs on the 15th. The meeting is expec
- Company
- No. of employees decline sharply due to restructuring/reorgs
- by Apr 12, 2022 06:04am
- The number of employees at multinational pharmaceutical companies has declined sharply due to their active restructuring and reorganizations. Over 200 employees have been laid off in just 4 companies - Roche Korea, Lilly Korea, Sanofi-Aventis Korea, and Zuellig Pharma Korea. According to the Financial Supervisory Service, the number of em
- Company
- Lutathera’s partner ‘LysaKare’ may be prescribed at GHs
- by Eo, Yun-Ho Apr 11, 2022 05:58am
- ‘LysaKare’, the drug concomitantly used with the neuroendocrine tumor treatment ‘Latathera’ may soon be prescribed at general hospitals. According to industry sources, Novartis Korea’s ‘LysaKare (L-arginine hcl/L-lysine hcl) has passed the drug committee (DC) reviews at 3 of the Big 5 general hospitals &8211; Samsung Medical Center
- Company
- HK inno.N's K-CAB has ended Phase 1 in US
- by Kim, Jin-Gu Apr 11, 2022 05:58am
- HK inno.N announced on the 7th that its flagship drug, "K-CAB (Tegoprazan), has successfully ended phase 1 clinical trials in the U.S., a treatment for gastroesophageal reflux disease. The clinical trial was conducted on 30 healthy adults with random assignment, double blinding, placebo control, and repeated administration. K-CAB 25 mg, 50
- Company
- Rising COVID-19 cases impede progress of bioequivalence test
- by Chon, Seung-Hyun Apr 8, 2022 06:08am
- Pharmaceutical companies are having trouble conducting bioequivalence tests for the development of generics due to COVID-19. The spread of COVID-19 has made it difficult for companies to recruit subjects, and even those recruited are dropping out after being confirmed with COVID-19, causing disruptions in the companies’ schedules. With del
- Company
- GC Pharma’s Hunterase ICV approved for P1T in Korea
- by Kim, Jin-Gu Apr 8, 2022 06:08am
- On the 7th, GC Pharma announced that it had received approval for a Phase I trial of its severe Hunter syndrome treatment ‘Hunterase ICV’ in Korea from the Ministry of Food and Drug Safety. Hunterase ICV comes in a new formulation that is inserted as a device in the head, through which a drug is directly administered into a patient’s
- Company
- Yuhan's gastric atony tx has completed the registration
- by Nho, Byung Chul Apr 8, 2022 06:08am
- Yuhan Corporation (CEO Cho Wook-je) announced on the 6th that it has completed the first patient registration in phase 2A of clinical trial for patients with gastric atony of the new drug candidate "YH12852 (PCS12852)" exported by Technology to Processa Pharmaceuticals. Gastric atony is a chronic gastric motor disorder that causes severe hear
- Company
- Organon Korea "No NDPA detected in Singulair”
- by Apr 7, 2022 06:10am
- Organon Korea announced on the 6th that no impurities were detected in ‘montelukast,’ the active ingredient of the allergic rhinitis and asthma treatment ‘Singulair.’ Organon Korea had conducted an impurity investigation for N- nitrosodipropylamine (NDPA) in January after the Ministry of Food and Drug Safety ordered companies to inves
- Company
- Competition for Pelubi's generics worth ₩30 billion
- by Kim, Jin-Gu Apr 7, 2022 06:10am
- It is expected that generic competition will take place in earnest in the Pelubi market, a osteoarthritis treatment worth 30 billion won per year. Following Youngjin Pharmaceutical, which launched generic alone, Huons and Chong Kun Dang are predicting their entry into the market. Daewon Pharmaceutical, which faces the challenge of generic
